| 29.03 -0.16 (-0.55%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.63 | 1-year : | 40.22 |
| Resists | First : | 32.22 | Second : | 34.43 |
| Pivot price | 30.74  |
|||
| Supports | First : | 28.62 | Second : | 23.82 |
| MAs | MA(5) : | 29.4 |
MA(20) : | 31.31 |
| MA(100) : | 31.76 |
MA(250) : | 32.22 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 15.5 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 39.26 | Low : | 18.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HRMY ] has closed above bottom band by 19.9%. Bollinger Bands are 28.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.7 - 29.9 | 29.9 - 30.07 |
| Low: | 28.54 - 28.74 | 28.74 - 28.9 |
| Close: | 28.75 - 29.06 | 29.06 - 29.32 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Thu, 18 Apr 2024
SGIOY: 3 Biotech Stocks to Buy to Power Through April - StockNews.com
Tue, 16 Apr 2024
HealthInvest Partners AB Takes $4.68 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Tue, 16 Apr 2024
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 - Yahoo Finance
Mon, 15 Apr 2024
The Law Offices of Frank R. Cruz Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of ... - The Globe and Mail
Mon, 15 Apr 2024
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harmony Biosciences Holdings, Inc ... - The Globe and Mail
Mon, 15 Apr 2024
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 19.3 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 6,350 (K) |
| Shares Short P.Month | 6,290 (K) |
| EPS | 2.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.22 |
| Profit Margin | 22.1 % |
| Operating Margin | 23.8 % |
| Return on Assets (ttm) | 16.1 % |
| Return on Equity (ttm) | 29.6 % |
| Qtrly Rev. Growth | 31.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 10.25 |
| EBITDA (p.s.) | 3.81 |
| Qtrly Earnings Growth | -43.5 % |
| Operating Cash Flow | 219 (M) |
| Levered Free Cash Flow | 215 (M) |
| PE Ratio | 13.62 |
| PEG Ratio | 0.4 |
| Price to Book value | 3.52 |
| Price to Sales | 2.83 |
| Price to Cash Flow | 7.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|